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ORIGINAL ARTICLE
SENP1 promotes hypoxia-induced cancer stemness
by HIF-1α deSUMOylation and SENP1/HIF-1α
positive feedback loop
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Eunice Yuen-Ting Lau,1,4 Yu-Man Tsui,1,3 Lo-Kong Chan,1,3 Tan-To Cheung,3,5
Kenneth Siu-Ho Chok,3,5 Albert C Y Chan,3,5 Regina Cheuk-Lam Lo,1,3
Joyce Man-Fong Lee,1 Terence Kin-Wah Lee,1,3,4 Irene Oi Lin Ng1,3
ABSTRACT
Objective We investigated the effect and mechanism
of hypoxic microenvironment and hypoxia-inducible
factors (HIFs) on hepatocellular carcinoma (HCC) cancer
stemness.
Design HCC cancer stemness was analysed by self-
renewal ability, chemoresistance, expression of stemness-
related genes and cancer stem cell (CSC) marker-positive
cell population. Speciﬁc small ubiquitin-like modiﬁer
(SUMO) proteases 1 (SENP1) mRNA level was examined
with quantitative PCR in human paired HCCs.
Immunoprecipitation was used to examine the binding of
proteins and chromatin immunoprecipitation assay to
detect the binding of HIFs with hypoxia response
element sequence. In vivo characterisation was
performed in immunocompromised mice and stem cell
frequency was analysed.
Results We showed that hypoxia enhanced the
stemness of HCC cells and hepatocarcinogenesis through
enhancing HIF-1α deSUMOylation by SENP1 and
increasing stabilisation and transcriptional activity
of HIF-1α. Furthermore, we demonstrated that SENP1 is
a direct target of HIF-1/2α and a previously
unrecognised positive feedback loop exists between
SENP1 and HIF-1α.
Conclusions Taken together, our ﬁndings suggest the
signiﬁcance of this positive feedback loop between HIF-
1α and SENP1 in contributing to the increased cancer
stemness in HCC and hepatocarcinogenesis under
hypoxia. Drugs that speciﬁcally target SENP1 may offer a
potential novel therapeutic approach for HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is a prevalent
malignancy and ranks third in cancer mortality
worldwide. Progression of HCC is believed to be
partly driven by cancer stem cell (CSC) through
their capacity of self-renewal, tumourigenicity, pro-
duction of heterogeneous progenies, metastasis and
resistance to chemotherapeutic drugs.1 Recently,
liver CSCs have been identiﬁed by cell surface
markers including CD133,2 CD90,3 epithelial cell
adhesion molecule,4 CD245 and CD47.6
Hypoxia is a common phenomenon in solid
cancers and is particularly frequent in HCC due to
its rapid growth.7 Hypoxia-inducible factors (HIFs)
are key transcription factors that allow cancer cells
to survive in hypoxia and composed of the stable
HIF-1β subunit and the oxygen-sensitive subunit
HIF-1/2α.7 With O2 (normoxia), HIF-1/2α is
hydroxylated and ubiquitin ligase Von
Hippel-Lindau then targets HIF-1/2α for ubiquitin-
proteasomal degradation. Without O2 (hypoxia),
HIF-1/2α is no longer degraded and binds with
HIF-1β to activate gene transcription and promote
tumour progression and metastasis.7 HIF-1α is a
master regulator contributing to the restoration of
oxygen homeostasis.7 In HCC, HIF-1α is closely
associated with poor prognosis of patients; HIF-1α
Signiﬁcance of this study
What is already known on this subject?
▸ Hepatocellular carcinoma (HCC) is a common
cancer and leading cause of death worldwide.
▸ Hypoxia is common in solid cancers and
particularly in HCC, which is a fast growing
cancer.
▸ Hypoxic microenvironment is an important stem
cell niche.
▸ SUMOylation is an important post-translational
protein modiﬁcation and involved in a wide
variety of cellular processes.
▸ Speciﬁc SUMO proteases 1 (SENP1) is able to
deSUMOylate hypoxia-inducible factor (HIF)-1α
and increase its stability in hypoxia.
What are the new ﬁndings?
▸ SENP1 is a direct target of HIF-1/2α.
▸ A previously unrecognised positive feedback
loop exists between SENP1 and HIF-1α.
▸ This positive feedback loop between HIF-1α
and SENP1 contributes to increased cancer
stemness of HCC and hepatocarcinogenesis
under hypoxia.
How might it impact on clinical practice
in the foreseeable future?
▸ Drugs that speciﬁcally target SENP1 may offer
a potential novel therapeutic approach for HCC.
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expression is high in HCCs with venous and lymph node metas-
tasis.8 Both HIF-1α and HIF-2α are induced by sorafenib in
HCC cells, and this contributes to the resistance to sorafenib,
the ﬁrst-line molecular drug for advanced HCC.9 10
Hypoxic microenvironment is an important stem cell niche
that promotes the persistence of CSCs in tumours.11 12
Increased levels of HIF-1α and HIF-2α were found in the stem
cell-like populations of neuroblastomas12 13 and gliomas.14
Similarly, HIF-2α is preferentially expressed in immature neural
crest-like neuroblastoma cells in vivo and may be required for
the maintenance of undifferentiated neuroblastoma cells.13
Induced cancer stem-like sphere cells from HCC cells had
higher HIF-1α mRNA levels and lower reactive oxygen species
activity.15 Furthermore, hypoxia increased the proportion of
HCC cells with stem-cell features, whereas echinomycin that
inhibits HIF-1α DNA binding activity blocked this effect.15 It is
unclear, however, how HIFs affect liver cancer stemness in
hypoxic condition.
SUMOylation is an important post-translational protein modi-
ﬁcation by small ubiquitin-like modiﬁer (SUMO) proteins,
which belong to the growing family of ubiquitin-like proteins.
SUMOylation is involved in a wide variety of cellular processes
such as transcription, DNA repair, trafﬁcking and signal trans-
duction.16 SUMOylation is carried out by a multistep enzymatic
cascade reaction facilitating the attachment of SUMO-1,
SUMO-2 or SUMO-3 to the substrates.17 18 SUMOylation is a
dynamic process and readily reversed by a family of speciﬁc
SUMO protease (SENPs), in a process called deSUMOylation,
in which SENPs remove SUMO conjugate from the conjugated
proteins.19 Six SENP proteins (SENP1, SENP2, SENP3, SENP5,
SENP6 and SENP7) have been identiﬁed in humans; each has
distinct subcellular localisation and substrate speciﬁcity, suggest-
ing that they are non-redundant.20–25
SENP1 has been shown to be essential for the stability and acti-
vation of HIF-1α and is able to deSUMOylate HIF-1α and
increase its stability in hypoxia.26 SUMOylation plays an import-
ant role in the regulation of HIF-1α26–28 but the impact of
SUMOylation on HIF-1α activity has been controversial.
Moreover, how SENP1 modulates HIF-1α affecting cancer stem-
ness is unknown. In this study, we report that SENP1 increases the
stabilisation and transcriptional activity of HIF-1α in hypoxia via
deSUMOylation in HCC. These enhance cancer stemness,
increase liver CSC subpopulations and promote hepatocarcinogen-
esis. In addition, we demonstrate that SENP1 is a direct target
gene of HIFs and a positive feedback loop exists between HIF-1α
and SENP1 and contributes to HCC stemness and tumourigenesis.
EXPERIMENTAL PROCEDURES
Cell culture, cloning procedures and transfection
All cell lines were maintained in Dulbecco’s modiﬁed Eagle’s
medium containing 1% penicillin and streptomycin, supplemen-
ted with 10% fetal bovine serum; 1% O2 was generated by
ﬂushing a 94% N2/5% CO2 mixture into the incubator. All
expression plasmids and transfections are shown in the online
supplementary experimental procedures.
Patient samples
Human HCCs and their paired non-tumourous liver (NT-L)
tissues were collected during surgical resection at Queen Mary
Hospital, Hong Kong. Use of human samples was approved by the
Institutional Review Board (IRB) of University of Hong Kong/
Hospital Authority Hong Kong West Cluster (IRB reference
number: UW09-185). Demographic information of the patients is
provided in online supplementary experimental procedures.
Chromatin immunoprecipitation assay
HCC cells were cross-linked with formaldehyde, lysed with
sodium dodecyl sulfate buffer and sonicated. Sheared DNA was
precleared with salmon sperm DNA/protein A agarose slurry
(Merck Millipore) and immunoprecipitated with HIF-1α or
HIF-2α antibody and IgG (Santa Cruz). Agarose beads were
incubated with antibody/protein/DNA complex and washed
with low-salt buffer, high-salt buffer and LiCl wash buffer
according to manufacturer’s protocol (Millipore). DNA was
eluted in and extracted by phenol-chloroform.
Cell sphere formation, proliferation, migration and
chemoresistance assays
Details are provided in the online supplementary experimental
procedures.
Immunohistochemistry, quantitative reverse transcription
PCR, short hairpin RNA, luciferase reporter assay,
immunoprecipitation and western blot analyses
Details are provided in the online supplementary experimental
procedures.
Animal experiments
Animal care and experiments were performed in strict accord-
ance with the ‘Guide for the Care and Use of Laboratory
Animals’ and ‘Principles for the Utilisation and Care of
Vertebrate Animals’ and were approved by the Experimental
Animal Ethical Committee at University of Hong Kong. The
detailed protocols are provided in the online supplementary
experimental procedures.
Statistical analysis
All statistical analyses were performed by the SPSS Statistics
SPSS 23.0. Student’s t-test, χ2 test or Mann-Whitney U test were
used for continuous data wherever appropriate. p Values <0.05
were considered to be statistically signiﬁcant.
RESULTS
Hypoxia enhances HCC stemness in HIF-1α-dependent and
HIF-2α-dependent manner
Digoxin, a well-known HIF-1α inhibitor, inhibits the transcrip-
tional activity of HIF-1α.29 First, we examined the effects of
digoxin on the mRNA expression of the different liver CSC
markers and sphere forming ability on two HCC cell lines
(MHCC-97L and PLC/PRF/5) by treating them with digoxin or
dimethyl sulfoxide for 24 hours under hypoxia. The mRNA
levels of CD24 and CD133 were consistently upregulated in
hypoxia, while digoxin treatment signiﬁcantly abolished this
upregulation (see online supplementary ﬁgure S1A). Similar
results were observed in sphere formation assay (see online
supplementary ﬁgure S1B).
To determine whether HIF-1α and HIF-2α regulate stemness
of HCC cells via speciﬁc molecular responses to hypoxia, we
generated stable HIF-1α or HIF-2α knockdown HCC cells
(MHCC-97L and PLC/PRF/5), as previously described.30
Knockdown of either HIF-1α or HIF-2α suppressed
hypoxia-induced transcription of HIF-target genes including
vascular endothelial growth factor (VEGF), lipoxygenase (LOX)
and erythropoietin (EPO) (see online supplementary ﬁgure S2).
Moreover, hypoxia enhanced the ability of self-renewal (in vitro
using sphere formation assay5 6 31) (see ﬁgure 1A and online
supplementary ﬁgure S3A), migration (see ﬁgure 1B and online
supplementary ﬁgure S3B) and chemoresistance to sorafenib and
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doxorubicin (see ﬁgure 1C and online supplementary
ﬁgure S3C). Upregulation of the mRNA levels of stemness-
related genes (Oct3/4, Nanog, Notch1 and B cell-speciﬁc
moloney murine leukemia virus integration site 1 (BMI-1)) was
also observed in HCC cells with hypoxic treatment (see ﬁgure
1D and online supplementary ﬁgure S3D). Knockdown of
HIF-1α or HIF-2α inhibited hypoxia-induced enhancement of
stemness in HCC cells (see ﬁgure 1A–D and online
supplementary ﬁgure S3A–D).
CD24+ tumour-initiating populations have been found in
HCC,5 pancreatic,32 colorectal33 34 and bladder cancers.35
Promoter analysis demonstrated that a hypoxia response
element (HRE) in the upstream promoter/enhancer region is
required for both hypoxia-induced and HIF-1α-dependent
CD24 expression.36 Previously, we reported that CD24 is a
functional liver CSC marker that drives CSC through
STAT3-mediated NANOG regulation.26 To determine the regu-
lation of CD24 by hypoxia in HCC cells, we assessed the
change of CD24+ cell population in hypoxia. After hypoxic
treatment, the CD24+ cell population rose from 12.6% to
21.7% and 30.6% to 62.8% in MHCC-97L and PLC/PRF/5
cells, respectively (see ﬁgure 1E and online supplementary ﬁgure
S3E). Similar but milder results were seen for CD133+ cells in
the HCC cell lines after hypoxic treatment (see online
supplementary ﬁgure S3E).
Furthermore, to address the inﬂuence of hypoxia on CD24+
and CD24− cells, we sorted CD24+ and CD24− subsets from
MHCC-97L cells using ﬂuorescence-activated cell sorting (FACS)
with good sorting efﬁciency (see online supplementary ﬁgure
S4A). High mRNA levels of CD24 and Nanog was observed in
the sorted CD24+ cells (see online supplementary ﬁgure S4B).
Next, we incubated CD24+ and CD24− cells in hypoxic or nor-
moxic conditions (ﬁgure 1F). We observed that the CD24+ cell
population was maintained at a signiﬁcantly higher level under
hypoxia than normoxia in both sorted CD24+ and CD24−
(ﬁgure 1F) MHCC-97L cells, which was abolished with digoxin
treatment (200 nM) in both CD24+ and CD24− HCC cells (see
online supplementary ﬁgures S4C). These data suggest that HIF
and/or hypoxia play an important role in the maintenance of
the CD24+ CSC subpopulation.
Figure 1 The effect of hypoxia and hypoxia-inducible factor (HIF)-1/2α on the stemness of MHCC-97L cells. (A–C) The in vitro cell abilities for
self-renewal (A), migration (B) and chemoresistance (C) to doxorubicin and sorafenib were enhanced under hypoxic condition (1% O2) in MHCC-97L
cells and the knockdown of HIF-1α or HIF-2α suppressed these hypoxia-induced effects. (D) Hypoxia-induced increase of mRNA expression of
stemness-related genes (Oct3/4, Nanog, BMI-1 and Notch1) was inhibited in HIF-1α or HIF-2α knockdown MHCC-97L cells. (E) CD24+ and CD133+
cell populations were increased in hypoxia-treated MHCC-97L cells, but the knockdown of HIF-1α or HIF-2α blunted the effects. (F) CD24+
population was analysed by FACS in sorted CD24+ (left) and CD24− (right) cells from MHCC-97L cells after cultured for indicated time under hypoxia
or normoxia. (*p<0.05, **p<0.01, ***p<0.001, compared with the negative control in normoxia (20% O2);
#p<0.05, ##p<0.01, ###p<0.001,
compared with the negative control in hypoxia (1% O2)).
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Overexpression of SENP1 in human HCCs and HCC cells
To delineate the roles of SENPs in hepatocarcinogenesis, we ﬁrst
assessed the mRNA levels of the six SENP family members in
human HCC tissues. From our RNA-sequencing data (available
in Sequence Read Archive of National Center for Biotechnology
Information with the accession number SRP062885) on 16
pairs of human HCCs and their corresponding NT-Ls as well as
The Cancer Genome Atlas (TCGA) data of National Cancer
Institute, USA (202 HCC tumours of all aetiologies including
‘unspeciﬁed’ aetiologies), we observed a consistent upregulation
of SENP1 (p=0.050 and p<0.001, respectively) (ﬁgure 2A, B).
Of note, SENP1 was consistently and signiﬁcantly upregulated
among the six SENP family members examined in these two
RNA-sequencing datasets, while this was not so for the other
ﬁve SENPs. Using quantitative PCR (qPCR) on our larger
cohort of 107 pairs of patients’ HCCs and corresponding
NT-Ls, we consistently observed signiﬁcant SENP1 upregulation
in the tumours (p=0.034) (ﬁgure 2C). Similarly, higher protein
expression level of SENP1 in human HCC was shown by immu-
nohistochemistry (IHC) (see online supplementary ﬁgure S5A).
We also examined the SENP1 expression using qPCR
and western blot analysis on a panel of HCC cell lines (Huh-7,
PLC/PRF/5, MHCC-97L, MHCC-97H, BEL-7402 and
SMMC-7721) and a non-tumourigenic immortalised normal
liver cell line MIHA. These HCC cell lines showed a range of
SENP1 mRNA and protein expression levels. In contrast,
MIHA, which is incapable of tumour formation in vivo, had
almost undetectable SENP1 protein level (see online
supplementary ﬁgure S6).
Clinical signiﬁcance of SENP1 and its correlation with HIF
target gene expression in human HCCs
On clinicopathological correlation, SENP1 overexpression (OE)
was signiﬁcantly associated with more aggressive tumour behav-
iour, in terms of more frequent venous invasion (p=0.042), a
feature of metastasis, and more advanced tumour stage
(p=0.034) (see online supplementary table S1).
To address the relationship of SENP1 and HIF signals, we
analysed the correlation between the mRNA levels of SENP1
and HIF-target genes using our RNA-sequencing data on 16
pairs of human HCCs. We observed a signiﬁcant positive correl-
ation between SENP1 and VEGFa, VEGFb, LOX, LOXL2 and
PLOD2 (ﬁgure 2D). Furthermore, we also found a positive cor-
relation between SENP1 and CD24 in this same cohort of
Figure 2 Upregulation of speciﬁc SUMO proteases 1 (SENP1) in hepatocellular carcinoma (HCC) tissues and the correlation between SENP1 and
hypoxia-inducible factor (HIF)-α target genes. (A and B) SENP1 was consistently and signiﬁcantly upregulated among the six SENP family members
examined in our RNA-sequencing data on 16 pairs of human HCCs and their corresponding non-tumourous livers (NT-Ls) and data from The Cancer
Genome Atlas (TCGA) of National Cancer Institute, USA (202 HCC tumours of all aetiologies including ‘unspeciﬁed’ aetiologies). (C) Using
quantitative PCR on a larger cohort of 107 pairs of HCC tumour and corresponding NT-Ls, the similar result of SENP1 upregulation in HCC tumours
was observed. (D) Correlation analysis of relative mRNA levels of SENP1 and VEGFa, VEGFb, LOX, LOXL2, PLOD2 or CD24 using our RNA-sequencing
data on 16 pairs of human HCCs and their corresponding NT-Ls.
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patients with HCC (p=0.024; r2=0.159) (ﬁgure 2D). In addi-
tion, using IHC, we examined the expression of two
HIF-1α-dependent genes, carbonic anhydrase 9 (CA9) and
glucose transporter 1 (GLUT1), and observed good correlation
among them in both mouse HCC xenograft (see online
supplementary ﬁgure S5B) and human HCCs (see online
supplementary ﬁgure S5C).
SENP1 OE enhances the expression of stemness-related
genes in HCC cells in hypoxia
To address whether SENP1 regulated cancer stemness through its
speciﬁc SENPs activity, we stably overexpressed SENP1 or
SENP1 catalytic inactive mutant (SENP1mut) (in which a
conserved amino acid, cysteine 603, in the catalytic domain
of SENP1 was substituted with alanine)26 in Huh-7 and
PLC/PRF/5 cells, to examine the functional roles of SENP1 in
maintaining liver CSCs in vitro (see online supplementary ﬁgure
S7). Huh-7 and PLC/PRF/5 cells were used in the OE experiment
as they have a relatively lower SENP1 endogenous level (see
online supplementary ﬁgure S6). The expression of SENP1, but
not SENP1mut, enhanced stemness-related properties, including
self-renewal ability (see ﬁgure 3A and online supplementary
ﬁgure S8A), cell migration (see ﬁgure 3B and online
supplementary ﬁgure S8B), CD24 cell population (see ﬁgure 3C
and see online supplementary ﬁgure S8C), expression of stemness
genes, Nanog and Oct4 (see ﬁgure 3D and online supplementary
ﬁgure S8D) and chemoresistance to sorafenib and doxorubicin
(ﬁgure 3E) under hypoxia. Increased cell proliferation was also
observed (see online supplementary ﬁgure S7).
Next, we tested the in vivo tumour initiating capacity of
SENP1. We injected SENP1-overexpressing Huh-7 cells or non-
target control (NTC) into nonobese diabetic/severe combined
immunodeﬁciency (NOD/SCID) mice subcutaneously at three
dilutions (5×103, 5×104 and 5×105) and let them grow for
6 weeks. The tumour initiating capacity was analysed by the CIs
for 1/(stem cell frequency) using extreme limiting dilution
analysis37 (see ﬁgure 3F and see online supplementary tables S2
and S3). The estimated CI for the frequency of CSCs in
SENP1-overexpressing group was 7121, as compared with
340 389 in NTC Huh-7 cells, indicating a much higher fre-
quency of CSCs in SENP1-overexpressing HCC cells
(p<0.001). These ﬁndings strongly suggest that SENP1
enhances hypoxia-induced cancer stemness in HCC cells, both
in vitro and in vivo.
SENP1 knockdown suppresses stemness features in hypoxia
We used a lentiviral-based approach to establish stable
SENP1-knockdown clones in MHCC-97L and BEL-7402 cells,
which have a higher SENP1 endogenous expression level (see
online supplementary ﬁgure S6). With successful SENP1 knock-
down (see online supplementary ﬁgure S9A, sequences #1 and
#4 had highest efﬁciency), we examined the stemness-associated
features in vitro. First, we found the mRNA expression levels of
liver CSC markers CD24, CD44 and CD133 were upregulated
by hypoxia treatment and SENP1 knockdown abolished this
response to hypoxia (see online supplementary ﬁgure S9B). By
sphere formation assay, SENP1 knockdown resulted in the for-
mation of fewer and smaller hepatospheres under hypoxia
(ﬁgure 4A). Moreover, shSENP1 cells had signiﬁcantly reduced
migratory ability under hypoxia (ﬁgure 4B). In addition, knock-
down of SENP1 suppressed the hypoxia-induced increase in
chemosensitivity to sorafenib and doxorubicin in MHCC-97L
cells (ﬁgure 4C). The CD24+ subpopulation, as detected using
FACS assay, was also signiﬁcantly reduced in SENP1-knockdown
HCC cells under hypoxia (ﬁgure 4D). Finally, the stemness-
related genes, Nanog, Notch1, Oct3/4 and BMI-1, were down-
regulated in the shSENP1 clones under hypoxia (ﬁgure 4E).
These results were similarly observed in BEL-7402 cells (see
online supplementary ﬁgure S10A–C).
We examined the tumourigenicity of HCC cells on SENP1
knockdown in vivo by subcutaneous injection of
SENP1-knockdown MHCC-97L cells or NTC into NOD/SCID
Figure 3 Effect of speciﬁc SUMO proteases 1 (SENP1) overexpression on the stemness of hepatocellular carcinoma (HCC) cells. (A–E) The effects
of overexpression of SENP1, SENP1mut and non-target control (NTC) on the stemness of HCC cells shown by in vitro abilities of self-renewal (A),
migration (B), CD24+ cell population (C) and mRNA expression of stemness-related genes (D) and chemoresistance (E), in hypoxic condition.
(F) Limiting dilution xenograft formation of Huh-7 cells with NTC or SENP1 overexpression. (*p<0.05, **p<0.01, compared with the negative
control in normoxia (20% O2), #p<0.05; ##p<0.01, compared with the negative control in hypoxia (1% O2)).
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mice at three dilutions (1×102, 1×103 and 1×104). The esti-
mated CI for the frequency of CSCs in SENP1-knockdown
group was 2722, compared with 249 in NTC MHCC-97L cells
(p<0.0001) (see ﬁgure 4F, online supplementary tables S4 and
S5). In addition, with in vivo tumour growth assay in nude
mice, the size of the tumours was smaller in the shSENP1
BEL-7402 (see online supplementary ﬁgure S10D) and
MHCC-97L (see online supplementary ﬁgure S11) clones when
compared with the NTC group. These data suggest that SENP1
knockdown suppresses hypoxia-induced cell stemness in HCC
cells and in vivo tumourigenicity. In addition, much reduced
expression of CA9 and GLUT1, the 2 HIF-1α targets, was
observed in the shSENP1 HCC cells in the xenografts in vivo
(see online supplementary ﬁgure S5B).
SENP1 is a direct target of HIF-1α and HIF-2α
To investigate whether SENP1 was regulated by HIF-α, we
examined the SENP1 mRNA and protein levels 24 hours after
hypoxic treatment. SENP1 expression was markedly increased
in MHCC-97L cells after hypoxic treatment (see online
supplementary ﬁgure S2 and ﬁgure 5A, B). These effects were
abolished when HIF-1α or HIF-2α was stably knocked down.
Furthermore, chromatin immunoprecipitation assay30 was used
to conﬁrm the binding of HIF-1α or HIF-2α to SENP1 pro-
moter. The HRE core sequence (A/G) CGTG was found at
around −498 and −489 bp in the SENP1 promoter.38 Using the
PCR primer sequences previously reported,38 we demonstrated
that HIF-1α, HIF-2α and HIF-1β bound to the HRE sequence
on the SENP1 promoter (ﬁgure 5C), strongly suggesting that
HIF is a transcriptional factor that regulates SENP1 expression
under hypoxia in HCC cells.
SENP1 enhances the stability and transcriptional activity of
HIF-1α through deSUMOylation
The correlation of SENP1 and hypoxia-induced HCC cell stem-
ness prompted us to investigate how SENP1 regulates HIF-α sta-
bility and transcriptional activity. As previously shown,26 SENP1
was able to deSUMOylate HIF-1α and increase its stability in
hypoxia. To this end, we examined the effect of SENP1 on
HIF-1/2α SUMO modiﬁcation, stability and transcriptional
activity in HCC cells. The protein level of HIF-1α but not
HIF-2α was reduced in SENP1-knockdown HCC cells in
hypoxia (ﬁgure 6A). Next, using immunoprecipitation (IP) assay,
we observed that in hypoxia, increased amounts of
SUMO1-conjugated or SUMO2/3-conjugated HIF-1α accumu-
lated in SENP1-knockdown HCC cells, as compared with NTC
(ﬁgure 6B). Consistent with the results of ﬁgure 6A, we found
very little detectable level of SUMOylated HIF-2α in both NTC
and SENP1-knockdown cells whether in hypoxia or normoxia
(ﬁgure 6B).
Then we assessed the transcriptional activity of HIF-1α on
VEGF using 6×HRE VEGF promoter driven-luciferase reporter
assay and qPCR. pGL3−6×VEGF HRE was cotransfected with
pSV40 into SMMC-7721 HCC cells with high efﬁciency.
Hypoxia-induced VEGF transcription was abolished in SENP1-
knockdown SMMC-7721 cells (see ﬁgure 6C and online
supplementary ﬁgure S12A). On the other hand, Huh-7 cells
with SENP1 OE displayed increased HIF-1α transcriptional activ-
ity in hypoxia, as compared with the NTC and SENP1-mut OE
controls (see ﬁgure 6D and online supplementary ﬁgure S12B).
Altogether, these results suggest that under hypoxia, SENP1
increases the stability and transcriptional activity of HIF-1α in a
SENPs-dependent manner.
Figure 4 Effect of speciﬁc SUMO proteases 1 (SENP1) knockdown on the stemness of hepatocellular carcinoma (HCC) cells. (A–E) The effects of
knockdown of SENP1 (shSENP1-#1 and shSENP1-#4) and non-target control (NTC) on the stemness of HCC cells shown by in vitro abilities of
self-renewal (A), migration (B) and chemoresistance (C), CD24+ cell population (D) and mRNA expression of stemness-related genes (E) in hypoxic
condition. (F) Limiting dilution xenograft formation of MHCC-97L cells with NTC or SENP1 knockdown. (*p<0.05, **p<0.01, ***p<0.001, as
compared with the negative control in normoxia (20% O2); #p<0.05, ##p<0.01, ###p<0.001, compared with the negative control in hypoxia
(1% O2)).
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Then we asked whether SUMO-mediated HIF-1α degradation
was dependent on proteasome signalling. We examined the
hypoxia-induced SUMOylation of HIF-1α in HCC cells with or
without treatment with MG132, a speciﬁc cell-permeable prote-
asome inhibitor. In hypoxia, HIF-1α protein level was increased
in SENP1-knockdown HCC cells with MG132 treatment, when
compared with untreated cells (see online supplementary
ﬁgure S12C). SUMOylated HIF-1α was easily detected in both
NTC and SENP1-knockdown cells exposed to hypoxia and
MG132 treatment. In contrast, without MG132 treatment, this
was undetectable and only weakly detectable in NTC and
SENP1-knockdown cells, respectively. These results suggest that
SUMOylated HIF-1α is degraded through a proteasome-
dependent mechanism in HCC cells.
SUMO sites K391 and K477 in HIF-1α are pivotal in
SENP1-regulated HIF-1α deSUMOylation
We assessed the effect of deSUMOylation on HIF-1α activity in
HCC cells using HIF-1α SUMOylated site mutants, K391R and
K477R.26 SUMOylation of exogenous HIF-1α was detected
through cotransfection of haemagglutinin (HA)-SUMO-1 and
regulation of G-protein signaling domain (RGS)-HIF-1α wild-
type (WT) or its mutants (RGS-HIF-1α K391R; RGS-HIF-1α
K477R) in HCC cells. As shown in ﬁgure 6E, SUMOylated
HIF-1α accumulated only in SENP1-knockdown HCC cells but
not in NTC cells, and the SUMO-1 conjugated HIF-1α was
markedly decreased in SENP1 knockdown cells transfected with
HIF-1α mutant (K391R and K477R). Furthermore, mutation of
the SUMOylation sites of HIF-1α signiﬁcantly increased the
transcriptional activity of HIF-1α in SENP1-knockdown cells
(see ﬁgure 6F and online supplementary ﬁgure S12D).
Mutation of the SUMO sites in HIF-1α rescues the loss of
hypoxia-induced stemness in SENP1-knockdown HCC cells
Since K391 and K477 SUMO sites are required by
SENP1-regulated HIF-1α deSUMOylation, we wondered if the
mutations of SUMO site in HIF-1α resisted the effect of SENP1
knockdown in HCC cells. To address this, we generated
MHCC-97L cells which stably overexpressed HIF-1α WT,
HIF-1α K391R, HIF-1α K477R or HIF-1α K391R/K477R
(HIF-1α SM, simultaneous double mutant). Western blot ana-
lysis conﬁrmed the overexpression of HIF-1α WT and mutants
in SENP1-knockdown cells or NTC (see online supplementary
ﬁgure S13). We found that stable transfection of HIF-1α WTor
HIF-1α mutants enhanced the stemness features including self-
renewal (ﬁgure 7A), cell migration (ﬁgure 7B), chemoresistance
(ﬁgure 7C), CD24+ cell population (ﬁgure 7D) and mRNA
expression of Oct3/4 and Nanog (ﬁgure 7E). However, SENP1
knockdown suppressed the effects of HIF-1α WT, while the
three HIF-1α mutants partially to almost completely rescued
HIF-1α-induced enhancement of HCC cell stemness in
shSENP1 cells.
HIF-1α knockdown suppresses SENP1-enhanced cancer
stemness in hypoxia
To further determine if the functional roles of SENP1 in
hypoxia were dependent on the activity of HIF-1α, we knocked
down the expression of HIF-1α or HIF-2α using lentivirus-
Figure 5 Speciﬁc SUMO proteases 1 (SENP1) play a role as the direct target gene of hypoxia-inducible factor (HIF)-1/2α in hepatocellular
carcinoma (HCC) cells. (A and B) Protein (A) and mRNA (B) levels of SENP1 were increased under hypoxia in HIF-1α-dependent and
HIF-2α-dependent manner in MHCC-97L cells. (C) Chromatin immunoprecipitation assay was used to determine the bind of HIF-1α, HIF-2α and
HIF-1β to the hypoxia response element (HRE) sequence in SENP1 promoter. (*p<0.05, **p<0.01, ***p<0.001, as compared with the negative
control in normoxia (20% O2); #p<0.05, ##p<0.01, ###p<0.001, as compared with the negative control in hypoxia (1% O2)).
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mediated short hairpin RNA in Huh-7 cells which overex-
pressed SENP1 (see online supplementary ﬁgure S14A). The
blockage of HIF-1α signal partly repressed the enhancement of
cell migration (see online supplementary ﬁgure S14B).
Furthermore, FACS results showed that HIF-1α knockdown
inhibited the increase of CD24+ cells induced by SENP1 in
hypoxia (see online supplementary ﬁgure S14C). There was also
chemoresistance to doxorubicin induced by SENP1 OE (see
online supplementary ﬁgure S14D). In contrast, these
stemness-associated features induced by SENP1 were unchanged
in the HIF-2α-knockdown HCC cells under hypoxia (see online
supplementary ﬁgure S14A–D).
DISCUSSION
In this study, our results show that SENP1 increases the stabilisa-
tion and transcriptional activity of HIF-1α under hypoxic condi-
tion via deSUMOylation. In addition, we have demonstrated
that SENP1 is a direct target gene of HIFs, and a previously
unrecognised positive feedback loop exists between HIF-1α and
SENP1 and contributes to HCC stemness and tumourigenesis.
Figure 6 Increased stability and transcriptional activity of hypoxia-inducible factor (HIF)-1α through deSUMOylation by speciﬁc SUMO proteases 1
(SENP1) in hepatocellular carcinoma (HCC) cells under hypoxic condition. (A) Western blot analyses were used to examine the protein level of
HIF-1α and HIF-2α in SENP1-knockdown and non-target control (NTC) HCC cells under hypoxia or normoxia. (B) immunoprecipitation (IP) assay was
used to detect the SUMOylation of HIF-1/2α by SUMO-1 or SUMO-2/3 in HCC cells. IP was conducted to obtain the complex protein with
anti-HIF-1α or anti-HIF-2α antibody in SENP1-knockdown or vehicle-infected SMMC-7721 cells, which were incubated under normoxia or hypoxia
for 24 hours. Western blot analyses were then carried out on the whole cell lysates and the IP complex with anti-SUMO-1 or SUMO-2/3 antibody.
Inputs are presented in the right-most panel. (C) Fold change of the relative luciferase activity was examined by luciferase-reporter assay in
SENP1-knockdown and NTC SMMC-7721 cells which were incubated under normoxia or hypoxia for 24 hours. (D) Fold change of the relative
luciferase activity was examined in NTC, SENP1 overexpression (SENP1 OE) and SENP1mut overexpression (SENP1mut OE) Huh-7 cells which were
incubated under normoxia or hypoxia for 36 hours. (E) IP assay was used to detect the binding of exogenous HIF-1α or the mutants with SUMO-1
in SMMC-7721 cells in normoxia. First, IP was conducted to obtain the complex protein with anti-HIF-1α antibody in SENP1-knockdown or
vehicle-infected SMMC-7721 cells, in which HA-SUMO-1 was cotransfected with RGS-HIF-1α wild type (WT), RGS-HIF-1α K391R, RGS-HIF-1α K477R,
or RGS-HIF-1α SM. Western blot analyses for indicated proteins in the whole cell lysates and the IP complex with anti-HA antibody. (F) Fold of the
relative luciferase activity was examined in SENP1-knockdown and NTC SMMC-7721 cells (in normoxia), in which HA-SUMO-1 was cotransfected
with RGS-HIF-1α WT, RGS-HIF-1α K391R, RGS-HIF-1α K477R or RGS-HIF-1α SM. (*p<0.05, **p<0.01, ***p<0.001, compared with the negative
control in normoxia (20% O2); #p<0.05, ##p<0.01, ###p<0.001, compared with the negative control in hypoxia (1% O2)).
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Our results have provided evidence of the effects of hypoxia
and HIF-1/2α on liver cancer stemness. The stemness-associated
features were signiﬁcantly enhanced in HCC cells in hypoxia,
while knockdown of HIF-1α or HIF-2α suppressed these
hypoxia-induced effects. Previously, we reported that CD24 is a
functional liver CSC marker that drives CSC through
STAT3-mediated NANOG regulation. Promoter analysis demon-
strates that a HRE located in the promoter/enhancer region is
required for both hypoxia-induced and HIF-1α-dependent
CD24 expression.36 Here, we consistently observed that hypoxia
maintained the CD24+ subpopulation in HCC cells in a
HIF-1/2α-dependent manner. Furthermore, CD24+ cell popula-
tions were maintained at a signiﬁcantly higher level under
hypoxia than normoxia in both sorted CD24+ and CD24− HCC
cells, while exposure to digoxin abolished these hypoxia-induced
effects in both CD24+ and CD24− HCC cells.
SUMOylation is known to regulate the functional activity of
some transcription factors associated with the acquisition of
CSC properties.39 So far, there is no report on whether SUMO
signalling is involved in the regulation of liver CSC properties
and hepatocarcinogenesis. We showed that in human HCCs, OE
of SENP1 was signiﬁcantly associated with more aggressive
tumour behaviour in terms of more advanced tumour stage and
presence of venous invasion. Functionally, SENP1 was able to
enhance the liver CSC properties. Furthermore, we revealed
that mechanistically, the regulation of SENP1 on
hypoxia-induced enhancement of liver CSC properties was
dependent on its catalytic activity, as inactivation of its catalytic
activity by speciﬁc mutants resulted in loss of such ability in
enhancing cancer stemness in hypoxia.
Increasing evidence has shown that HIF-1α is an important
SUMO substrate, although HIF-1α SUMOylation and its effects
Figure 7 Mutation of SUMO sites rescues the loss of hypoxia-induced stemness in speciﬁc SUMO proteases 1 (SENP1)-knockdown hepatocellular
carcinoma (HCC) cells. The effects of SENP1 knockdown on the stemness of HCC cells with overexpressing hypoxia-inducible factor (HIF)-1α wild
type (WT), HIF-1α K391R, HIF-1α K477R or HIF-1α SM. In vitro abilities of self-renewal (A), migration (B) and chemoresistance (C), CD24+ cell
population (D) and mRNA expression of stemness-related genes (E) were determined in hypoxic condition. SENP1 knockdown suppressed the effects
of HIF-1α WT, while the three HIF-1α mutants partially to almost completely rescued HIF-1α-induced enhancement of HCC cell stemness in shSENP1
HCC cells. (F) A cartoon summarising our ﬁndings. HIF-1/2α induced by the hypoxic microenvironment increases the transcription of SENP1 in HCC
cells. SENP1 represses the SUMOylation of HIF-1α at K391 and K477 by its SUMO protease activity, thus enhancing the stability and transcriptional
activity of HIF-1α. These in turn upregulate the expression of HIF target genes, including SENP1 and stemness-related genes, and contribute to the
increased stemness properties. (*p<0.05, **p<0.01, ***p<0.001, as compared with the negative control).
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vary among cell types.27 28 40 41 42 43 With regard to
deSUMOylation, here, we show that SENP1 increased the stability
and transcriptional activity of HIF-1α by deSUMOylation at K391
or K477 residues of HIF-1α in HCC cells. SENP1 knockdown sig-
niﬁcantly increased the accumulation of SUMO-1-conjugated
HIF-1α and decreased the HIF-1α protein level under hypoxia in
HCC cells. Consistently, hypoxia-induced transcriptional activity
of HIF-1α on VEGF was inhibited by SENP1 knockdown in HCC
cells. On the contrary, mutation of the SUMO sites at K391 and
K477 of HIF-1α, either singly or combined, alleviated the inhibi-
tory effect of SENP1 knockdown on HIF-1α activity and liver
CSC properties. However, we failed to detect signiﬁcant conjuga-
tion of SUMO with HIF-2α in HCC cells, although it was
reported that HIF-2α was also regulated by SUMO and SENP1 in
HeLa cells.43 Functionally, knockdown of HIF-1α, but not
HIF-2α, partially suppressed SENP1-enhanced stemness of HCC
cells in hypoxia. From our results, SENP1 is able to enhance HCC
stemness properties by reducing the SUMOylation and increasing
the stability and transcriptional activity of HIF-1α in hypoxia. In
previous studies, SENP1 has been identiﬁed as an erythropoiesis
regulator as well as being essential for the stability and activity of
HIF-1α by deSUMOylation.26 SENP1 also contributes to the pro-
gression of prostate cancer through stabilising HIF-1α and enhan-
cing VEGF production and angiogenesis.38 Nonetheless, it is the
ﬁrst time that SENP1 is reported to be involved in liver CSC prop-
erties and hepatocarcinogenesis via regulation of HIF-1α
deSUMOylation in hypoxia.
Interestingly, we found that SENP1 was induced by hypoxia
as a direct target of HIF-1α and HIF-2α in HCC cells, in line
with a previous report on endothelial cell model.38 Of signiﬁ-
cance, we have demonstrated a previously unrecognised positive
feedback loop between HIF-1α and SENP1, which contributes
to the maintenance of HCC stemness and tumourigenesis under
hypoxia. Overall, as a summary of our ﬁndings in this study
(ﬁgure 7F), HIF-1/2α, as induced by hypoxic microenviron-
ment, increases the transcription of SENP1 in HCC cells.
SENP1 represses the SUMOylation of HIF-1α at K391 and
K477 by its SENPs activity, which decreases the stability and
transcriptional activity of HIF-1α, thus increasing the expression
of HIF target genes, including SENP1 and stemness-related
genes (Nanog, Oct4 and CD24), and contributing to the
enhancement of stemness properties. Developing new inhibitors
that speciﬁcally target SENP1 may offer a novel therapeutic
approach to block HCC growth, metastasis and recurrence.
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